CTOs on the Move

SwanBio Therapeutics

www.swanbiotx.com

 
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.swanbiotx.com
  • 150 Monument Road Suite 207
    Bala Cynwyd, PA USA 19004
  • Phone: 610.557.0600

Executives

Name Title Contact Details
Scott McMillan
Chief Technical Officer Profile

Funding

SwanBio Therapeutics raised $52M on 04/23/2020

Similar Companies

Crosscart Inc

Crosscart Inc is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeruoGenomeX

NeruoGenomeX, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuneering

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.